Abstract:<span class="paragraphSection">BackgroundLarotrectinib is the first therapy approved in the U.S. for locally advanced or metastatic solid tumors with neurotropic tyrosine receptor kinase (NTRK) gene fusions. NTRK gene fusions have been documented with variable frequency across numerous tumor types; limited data exist regarding the relationship of NTRK gene fusions with other targetable biomarkers. This study evaluated the co-occurrence of NTRK gene fusions with other therapy molecular markers in cancer patients.MethodsThis retrospective study included cancer patients from a de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB) who had next-generation sequencing (NGS) between Jan 2011 and July 2018. The co-occurrence frequencies of NTRK gene fusions with the following markers was determined using NGS assays including FoundationOne and FoundationOne Heme: tumor mutation burden (TMB), microsatellite instability (MSI), ALK, BRAF, ERBB2, EGFR, ROS1, and KRAS.ResultsAn evaluable sample of 15,971 of 33,398 patients in the CGDB had one of 18 histologies where at least one NTRK fusion patient was identified. NTRK gene fusions were identified in 29 patients: 55% (16/29) were female; 69% (20/29) were Caucasians. The median age was 60 years (Q1-Q3: 49.0-65.0). Fifteen different fusion partners were identified; the most frequent were ETV6-NTRK3 (n = 8), TPM3-NTRK1 (n = 6), and TPR-NTRK1 (n = 3). Co-occurring genomic alterations are shown in the table. Table: 102PCo-occurring biomarkers**Patients with NTRK gene fusions (N = 29), % (n)TMB High (>20 mut/mB) TMB Medium (<20, >5 mut/mB)20.7 (6/29) 10.3 (3/29)MSI (high)17.6 (3/17)****ALK rearrangement0.0 (0/29)BRAF alteration3.5 (1/29)ERBB2 amplification0.0 (0/29)EGFR alteration3.5 (1/29)ROS1 alteration0.0 (0/29)KRAS alteration10.3 (3/29)*Variants of "known" or "likely" functional status were included**MSI status missing for 12 patientsConclusionsThe study confirmed the rarity of NTRK gene fusions in cancer patients. Co-occurrence of the biomarkers ALK, BRAF, ERBB2, EGFR, ROS1, or KRAS was uncommon. These results highlight the importance of identifying patients with NTRK gene fusion-driven cancers, through molecular testing, who will benefit from the use of selective TRK kinase inhibitors across different solid tumors.Editorial acknowledgementMichael Sheldon, PhD, of Scion, London, UK, funded by Bayer.Legal entity responsible for the studyBayer.FundingBayer.DisclosureX. Jiao: Full / Part-time employment: Bayer. A. Lokker: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: CVS Health, Roche, Medtronic, Sangamo Therapeutics. J. Snider: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: Roche. E. Castellanos: Full / Part-time employment: Flatiron Health. S. Nanda: Full / Part-time employment: Bayer. V. Fisher: Full / Part-time employment: Foundation Medicine. J. Zong: Full / Part-time employment: Bayer. K. Keating: Full / Part-time employment: Bayer. M. Fellous: Full / Part-time employment: Bayer.</span>

Large-Scale Study Of Ntrk Fusions In Chinese Solid Tumors And Using Next Generation Sequencing: A Multicenter Study

Characterization of NTRK gene fusion events in solid tumors among Chinese patients.

China Special Issue on Gastrointestinal Tumors—ntrk Fusion in a Large Real‐world Population and Clinical Utility of Circulating Tumor DNA Genotyping to Guide TRK Inhibitor Treatment

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

Expert Consensus on the Diagnosis and Treatment of NTRK Gene Fusion Solid Tumors in China

Identification of NTRK Gene Fusions in Lung Adenocarcinomas in the Chinese Population

Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

P1.03-23 the Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study

NTRK gene fusion testing and management in lung cancer

NTRK -rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China

The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan

The Genomic Profiling in Chinese Head and Neck Cancer and Incidence of NTRK Fusion

Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib

Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer